Skye Bioscience Inc. is a biopharmaceutical company focused on the development of proprietary, synthetic cannabinoid derived molecules for the treatment of diseases with significant unmet needs. The company’s lead molecule, in preclinical studies, has demonstrated potential as a new class of therapy to lower intraocular pressure in patients with glaucoma or elevated intraocular pressure that is superior to currently available drugs.